Otlertuzumab
Otlertuzumab
Main page

Otlertuzumab

logo
Community Hub0 subscribers
What are your thoughts?
Be the first to start a discussion here.
Be the first to start a discussion here.
Otlertuzumab

Otlertuzumab (TRU‐016) is a humanized monoclonal antibody that targets CD37 designed for the treatment of cancer.

This drug was developed by Emergent BioSolutions and has been in clinical trials for lymphoma and Chronic Lymphocytic Leukemia (CLL)

See all
User Avatar
No comments yet.